(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 December 2020 (17.12.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/249687 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01)

(21) International Application Number:
PCT/EP2020/066226

(22) International Filing Date:
11 June 2020 (11.06.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/860,182	11 June 2019 (11.06.2019)	US
62/924,356	22 October 2019 (22.10.2019)	US
62/932,160	07 November 2019 (07.11.2019)	US

(71) Applicant: **ALKERMES PHARMA IRELAND LIMITED** [IE/IE]; Connaught House 1 Burlington Road, Dublin 4 (IE).

(72) Inventors: **LOSEY, Heather C.**; 12 Taft Avenue, Lexington, MA 02421 (US). **SUN, Lei**; P.O. Box 550221, Waltham, MA 02455 (US).

(74) Agent: **KILBURN & STRODE LLP**; Lacon London 84 Theobalds Road, London WC1X 8NL (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY




FIG. 1

(57) Abstract: The invention provides compositions and improved methods for the treatment of cancer using IL-2 immunotherapy. The methods of the invention comprise administering to a patient, the fusion protein of SEQ ID NO: 1 at a dose of about 6 μg/kg/day to about 70 μg/kg/day and preferably at a dose of at least about 6 μg/kg/day to about 15 μg/kg/day or at a corresponding fixed per day dose based, for example, on an average about 60 to about 70 kg adult human or based, for example, on a child of about 12 kg to about 50 kg or more, wherein administration results in a dose dependent increase in circulating NK cells and CD8+ cells in a patient in the absence of a dose dependent increase in circulating immunosuppressive T regulatory (Treg) cells and preferably wherein the increase in circulating NK cells and CD8+cells is greater relative to the increase in circulating T Treg cells.

WO 2020/249687 A1

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*